About Threonine
Essential amino acid, precursor to glycine, and a normal constituent of dietary protein. Small neurology trials tested 4-7.5 g/day for spinal/MS spasticity (modest, inconsistent antispasticity effect) and 4 g/day in ALS (a controlled trial found no benefit on disease course). No evidence supports free-form threonine as a general wellness supplement. Grade low: only small, mixed-to-null clinical trials in specific neurological conditions.
What Threonine supports
- Building block for protein and a precursor to glycine (mechanistic)
- Tested for spasticity in neurological disease with weak, inconsistent results
How much Threonine to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
500–4000
mg
No established general therapeutic dose; nominal range for a blend component. Neurology trials used 4-7.5 g/day for spasticity/ALS.
Clinical evidence
Limited clinical evidence. Essential amino acid; small mixed-to-null trials in spasticity/ALS. No general-use evidence.
NIH Fact Sheet